CG Oncology (CGON) Cash from Financing Activities (2023 - 2026)

CG Oncology's Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $393.0 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 87232.89% year-over-year to $393.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $546.1 million (up 141.58% YoY) and the FY2025 annual result came in at $153.6 million, down 75.55% from the prior year.
• Cash from Financing Activities was $393.0 million for Q1 2026 at CG Oncology, up from $99.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $402.7 million in Q1 2024 and bottomed at -$15.2 million in Q2 2023.
• A 4-year average of $97.1 million and a median of $2.2 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2025 — Cash from Financing Activities plunged 840.0% — and 2026, when it soared 87232.89%.
• CG Oncology's Cash from Financing Activities stood at -$2.9 million in 2023, then soared by 7814.57% to $223.4 million in 2024, then slumped by 55.66% to $99.1 million in 2025, then surged by 296.7% to $393.0 million in 2026.
• Business Quant data shows CGON's Cash from Financing Activities at $393.0 million in Q1 2026, $99.1 million in Q4 2025, and $54.4 million in Q3 2025.